Insys Therapeutics, Inc. (INSY): Theodore H Stanley , director of Insys Therapeutics, Inc. sold 16,000 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 6, 2016 to the Securities and Exchange Commission. The shares were sold at $16.27 per share for a total value of $260,320.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 12, 2016, John N Kapoor (CEO) purchased 50,000 shares at $12.68 per share price.On Mar 7, 2016, Patrick Fourteau (director) sold 15,000 shares at $18.22 per share price.Also, On Mar 4, 2016, Theodore H Stanley (director) sold 20,000 shares at $18.11 per share price.On Jun 10, 2015, Fosse Franc Del (General Counsel) sold 10,000 shares at $34.48 per share price.
Shares of Insys Therapeutics Inc (INSY) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -1.23 points or -7.24% at $15.77 with 7,87,872 shares getting traded. Post opening the session at $16.99, the shares hit an intraday low of $15.71 and an intraday high of $16.99 and the price vacillated in this range throughout the day. The company has a market cap of $1,128 M and the number of outstanding shares has been calculated to be 7,15,46,491 shares. The 52-week high of Insys Therapeutics Inc is $46.17 and the 52-week low is $12.21.
Company has been under the radar of several Street Analysts.Insys Therapeutics Inc is Reiterated by Jefferies to Buy while Lowering the Price Target of the company shares to $ 17 from a previous price target of $23 . The Rating was issued on Apr 12, 2016.Insys Therapeutics Inc is Reiterated by Piper Jaffray to Overweight while Lowering the Price Target of the company shares to $ 28 from a previous price target of $46 . The Rating was issued on Apr 11, 2016.
Insys Therapeutics Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule a generic equivalent to Marinol (dronabinol) an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. The Companys lead product candidate is Dronabinol oral solution an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.